Broad Neuraminidase Inhibition by Human Antibodies
Author Information
Author(s): Lederhofer Julia, Borst Andrew J., Nguyen Lam, Gillespie Rebecca A., Williams Connor J., Walker Emma L., Raab Julie E., Yap Christina, Ellis Daniel, Creanga Adrian, Tan Hyon-Xhi, Do Thi H. T., Ravichandran Michelle, McDermott Adrian B., Sage Valerie Le, Andrews Sarah F., Graham Barney S., Wheatley Adam K., Reed Douglas S., King Neil P., Kanekiyo Masaru
Primary Institution: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Hypothesis
Can human monoclonal antibodies effectively target and inhibit the neuraminidase of various influenza viruses?
Conclusion
The study demonstrates that human monoclonal antibodies can broadly inhibit neuraminidase activity across multiple influenza virus strains.
Supporting Evidence
- NCS mAbs recognized multiple neuraminidase subtypes and conferred protection in mice.
- Structural analysis revealed that NCS mAbs mimic the substrate of neuraminidase.
- Water molecules play a crucial role in stabilizing the binding of NCS mAbs to neuraminidase.
Takeaway
Scientists found that certain human antibodies can stop the flu virus from spreading by blocking a part of the virus called neuraminidase.
Methodology
The study involved isolating human monoclonal antibodies from a convalescent individual and characterizing their binding and inhibitory effects on neuraminidase using various assays.
Limitations
The study primarily focused on in vitro and murine models, which may not fully represent human responses.
Participant Demographics
The study involved a single male donor who had a documented H3N2 infection.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website